[{"orgOrder":0,"company":"Asgard Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Asgard Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asgard Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Asgard Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Asgard Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"AT-108","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Asgard Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asgard Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Asgard Therapeutics \/ Johnson & Johnson Innovative Medicine"}]

Find Clinical Drug Pipeline Developments & Deals by Asgard Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The financing aims to support the ongoing development of the lead program AT-108. Currently, it is being evaluated in the preclinical trial studies for neoplasms in the form of tailored treatment.

                          Product Name : AT-108

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 14, 2024

                          Lead Product(s) : AT-108

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : $32.7 million

                          Deal Type : Series A Financing

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The financing will enable Asgard Therapeutics to expand pipeline of preclinical assets and build on making personalized cancer immunotherapies optimized to unique patient. Funds will be used to further develop personalized therapy programs for multiple o...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 11, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Organovo Holdings

                          Deal Size : $6.8 million

                          Deal Type : Financing

                          blank